Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 (PRNewswire) - Sep 30, 2026 - "Bempikibart demonstrated clinically meaningful efficacy data on primary and key secondary endpoints at Week 36 supporting its advancement into a registration-directed program. Mean percent reduction in SALT score from baseline of 35.3% in the mITT analysis. 40.0% (10/25) of patients in the mITT analysis and 30.3% (10/33) of patients in the intent-to-treat ('ITT') analysis achieved a SALT-20 response. In addition to SALT-20 response being observed in patients with both severe and very severe disease, it was also observed in both IgE-high and IgE-low patients and in both patients with greater than and less than two-year duration of episode."
Late-breaking abstract • P2a data • Alopecia • Immunology
|